Shetal Vyas

Shetal Vyas is a seasoned leader in the life sciences sector, currently serving as an Advisory Board Member for Aquent and as an Independent Board Director for KJT. With a proven track record at Ferring Pharmaceuticals, Shetal launched the first-ever gene therapy for bladder cancer and held multiple vice president roles focused on operations and business unit leadership. Previous experience includes significant marketing leadership positions at Pentec Health and Vermillion, Inc., where Shetal drove substantial revenue growth and market development. An educational background includes advanced management programs at Harvard Business School and an MBA in Marketing from Saint Joseph's University.